Picture of Sequana Medical NV logo

SEQUA Sequana Medical NV Share Price

0.000.00%
be flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-5.39%
3m+12.28%
6m-32.21%
1yr-48.77%
Volume Change (%)
10d/3m+100.06%
Price vs... (%)
52w High-50.66%
50d MA-19%
200d MA-7.79%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-268.52%
Return on Equity-690.43%
Operating Margin-3587.84%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Sequana Medical NV EPS forecast chart

Profile Summary

Sequana Medical NV is a Belgium-based company, which manufactures medical devices. The Company focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.

Directors

Last Annual
December 31st, 2022
Last Interim
June 30th, 2023
Incorporated
December 31st, 2018
Public Since
February 11th, 2019
No. of Employees
60
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
be flag iconEuronext - Brussels
Shares in Issue
28,242,753
Blurred out image of a map
Address
Kortrijksesteenweg 1112, GENT, 9052
Web
https://www.sequanamedical.com/
Phone
+32 92928065
Auditors
PricewaterhouseCoopers Bedijfsrevisoren

SEQUA Share Price Performance

Upcoming Events for SEQUA

Sequana Medical NV Annual Shareholders Meeting

Similar to SEQUA

Picture of argenx SE logo

argenx SE

be flag iconEuronext - Brussels

Picture of Celyad Oncology SA logo

Celyad Oncology SA

be flag iconEuronext - Brussels

Picture of Oxurion NV logo

Oxurion NV

be flag iconEuronext - Brussels

FAQ